H. Popper (Graz, Austria), D. Cataldo (Liege, Belgium)
Lactat-dehydrogenase, C-reactive protein and white blood cell count are prognostic factors in advanced small cell lung cancer (SCLC)
T. Weiss, J. Kollmeier, T. G. Blum, C. Boch, C. Crolow, D. Misch, S. Thiel, H. Rüssmann, T. T. Bauer (Berlin, Germany)
|  |
Does smoking status at time of diagnosis of lung cancer independently predict survival at 6 months?
R. Roberts, K. Lewis (Llanelli, Swansea, United Kingdom)
|  |
Systemic inflammation, nutritional status and tumor immune microenvironment determine outcome in resected non-small cell lung cancer
M. Alifano, A. Lupo, N. Roche, A. Bobbio, J. F. Regnard, I. Cremer, M. C. Dieu-Nosjean, D. Damotte (Paris, France)
| |
Significance of EGFR expression patterns in patients with non-small cell lung cancer – Evaluation on protein- and/or gene level?
R. Gaber, I. Watermann, C. Kugler, N. Reinmuth, R. M. Huber, P. Schnabel, E. Vollmer, M. Reck, T. Goldmann (Borstel, Großhansdorf, Borstel, Lübeck, Kiel, Großhansdorf, Munich, Heidelberg, Germany; Alexandria, Egypt)
| |
Integrative analysis of DNA copy number in metastatic NSCLC identifies drug sensitivity to Afatinib
M. Xie, S. H. Wei, M. He (Guangzhou, Beijing, Shanghai, China)
| |
Novel two mechanisms for acquired EGFR-TKI resistance in lung cancer cells harboring EGFR activating mutation
H. Izumi, R. Kanda, Y. Murakami, Y. Morimoto, M. Ono (Kitakyushu, Fukuoka, Japan)
| |
Correlation between the simultaneus expression of HER2 and PTEN and the risk of development of metastasis in NSCLC
A. Stamatelopoulos, E. Tsiambas, N. Atzoulatos, P. Michos, I. Gakidis, D. Bouros (Athens, Alexandroupolis, Greece)
| |
The value of miR221 and miR222 as a biomarker in non small cell lung cancer
Y. Musteri Oltulu, E. Coskunpinar, E. Aynaci, P. Yildiz, I. Yaylim (Istanbul, Turkey)
| |
The prognostic value of KRAS mutation according to the gene's
C. Boch, J. Kollmeier, A. Roth, D. Misch, T. Weiß, A. Streubel, T. Mairinger, T. T. Bauer (Berlin, Germany)
| |
Immunohistochemical expression of nuclear factor kappa-B/p65 and cyclooxygenase-2 in non-small cell lung cancer patients: Prognostic value and impact on survival
G. H. Abo El-Magd, O. Abd El-Fattah, E. M. Saied (Tanta, Egypt)
| |
Prognostic value and functional characterization of miR-141 and miR-200c expression levels in resected NSCL
J. Moisés, R. Marrades, R. Tejero, A. Navarro, M. Campayo, N. Viñolas, C. Agustí, A. Saco, M. Paradela, L. Molins, J. Ramirez, M. Monzó (Barcelona, Spain)
| |
A functional polymorphism in XRCC1 gene is associated with lung cancer risk in a Korean population
S. S. Yoo, C. Jin, K. J. Choi, S. Y. Lee, Y. D. Lee, S. Y. Lee, J. Lee, S. I. Cha, C. H. Kim, J. Y. Park (Daegu, Republic Of Korea)
| |
Clinicopathological prognostic factors in operated for pulmonary carcinoid tumor patients
D. Marinova, Y. Slavova, P. Titorenkov, D. Kostadinov, M. Tafradjiiska, E. Goranov, D. Petrov (Sofia, Bulgaria)
| |
Serum IL-33 as a diagnostic and prognostic marker in non- small cell lung cancer
M. Petrovic, I. Cekerevac, D. Petrovic, R. Vucic, I. Simic (Kragujevac, Republic Of Serbia)
| |
Differences in expression and prognostic values of p16(ink) and VEGF in squamous and adenocarcinoma of the lung
R. Sejdinovic, E. Jusufovic, F. Ljuca, D. Keser, M. Osmic, B. Prnjavorac, E. Zukic, E. Budisin, J. Alidzanovic (Tesanj, Zenica, Tuzla, Sarajevo, Bosnia And Herzegovina; Sremska Kamenica, Republic Of Serbia)
| |
Simultaneous EGFR and VEGF alterations in non-small cell lung carcinoma based on tissue microarrays
A. Stamatelopoulos, E. Tsiambas, I. Gakidis, P. Michos, D. Bouros, N. Atzoulatos (Athens, Alexandroupolis, Greece)
| |